Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $12.8M fell 16.7% year over year, behind the -13.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.3% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.

Context

  • Depreciation & amortization amounted to 34.7% of revenue in FY2025, up 6.9 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -16.7% toward the trailing-twelve-month pace of -13.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.8M-6.3% QoQ
Last fiscal yearDec 2025
$58.99M-6.4% YoY
LTMMar 2026
$56.42M-13.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.7%——
1 year-6.4%——
3-year CAGR+11.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
58.99M USD
Year-over-year change
-6.4%
4-year CAGR
+19.3%

Depreciation & Amortization vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.9% is the 7th highest of 9, against a peer median of +29.0%.
  • Depreciation & amortization amounts to 39.9% of revenue for DNA, versus a peer median of 21.7%.
DNA Competitors
Depreciation & Amortization for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$56.96M USD-3.2%+16.6%27.3%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$56.42M USD-13.9%+11.5%39.9%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$33.47M USD-27.6%+30.8%8.8%
MGTXMeiraGTx Holdings plcLTM Mar 2026$28.32M USD+126.8%+13.8%35.5%
VALNValneva SELTM Mar 2026€25.21M EUR+138.6%+1.1%16.1%
VIRVir Biotechnology, Inc.LTM Mar 2026$18.23M USD+41.3%+46.1%27.8%
ARVNArvinas, Inc.LTM Mar 2026$5M USD-19.4%-14.1%5.6%
REPLReplimune Group, Inc.LTM Dec 2025$3.98M USD+18.5%+17.7%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$3.59M USD———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$343K USD+39.4%+64.2%—
Peer median (excluding DNA) —+29.0%+17.2%21.7%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.84B)(2.11B)(892.87M)(547.03M)(312.76M)
Depreciation & Amortization29.08M42.55M71.55M63.02M58.99M
Deferred Income Tax30.21M(14.61M)(801K)(936K)(1.36M)
Stock-Based Compensation1.61B1.93B229.88M112.34M81.55M
Change in Working Capital(61.54M)(37.01M)29.84M(89.67M)(44.09M)
Accounts Receivables(114.09M)55.02M50.07M(4.73M)(1.47M)
Inventory(626K)164K000
Accounts Payables(2.25M)(10.84M)(1.18M)4.77M(2.99M)
Other Working Capital55.43M(81.35M)(19.05M)(89.72M)(39.62M)
Other Non-Cash Items(20.95M)(67.4M)266.9M142.69M46.62M
Operating Cash Flow(253.82M)(252.2M)(295.5M)(319.59M)(171.06M)
Capital Expenditures(56.52M)(52.27M)(40.8M)(62.54M)(7.67M)
Acquisitions (Net)(12.04M)26.65M(38.55M)(5.4M)0
Purchases of Investments(5M)(3.69M)00(418.63M)
Sales of Investments0004.52M185.38M
Other Investing Activities304K(38.08M)(1.34M)1.19M624K
Investing Cash Flow(73.26M)(67.39M)(80.69M)(62.24M)(240.29M)
Debt Repayment(1.12M)(1.24M)(1.3M)(897K)(354K)
Common Stock Issued099.3M080K19.47M
Common Stock Repurchased(25M)0(23K)00
Dividends Paid00000
Other Financing Activities1.56B(2.73M)(1.43M)(922K)(1.34M)
Financing Cash Flow1.53B95.34M(3.22M)(1.74M)17.78M
Effect of Forex Changes(19K)908K(588K)(281K)395K
Net Change in Cash1.21B(223.35M)(380M)(383.84M)(393.18M)
Free Cash Flow(310.34M)(304.47M)(336.3M)(382.13M)(178.72M)

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.